Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
C4T halts BRAF degrader work to save cash for cemsidomide
C4 Therapeutics is ending work on its clinical-stage BRAF degrader program to focus on its IKZF1/3 degraded cemsidomide.
James Waldron
May 7, 2025 7:00am
British biotech CellCentric expands to Boston, plans hiring push
Apr 2, 2025 1:53pm
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
Exicure buys GPCR's US unit and clinical-stage blood cancer drug
Jan 23, 2025 5:01am
JPM25: AbbVie pens $1B deal for Simcere’s ph. 1 T-cell engager
Jan 13, 2025 10:28am
Mountainfield, China's Keymed launch biotech with $180M series A
Jan 10, 2025 8:43am
